Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥134.00 - ¥417.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥2.67B
Enterprise Value¥608.57M
Total Cash (Recent Filing)¥1.52B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-48.18
Shares Outstanding18,429,500
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth over multiple years shows expanding product adoption and market traction. That scale increases optionality to leverage fixed costs, improve operating leverage over time, and supports long-run investment in R&D or commercial expansion without relying solely on transient demand spikes.
Conservative Balance Sheet (no Debt)Having no reported debt reduces bankruptcy risk and interest expense pressure, preserving flexibility to fund operations or pursue strategic actions. A strong asset base provides collateral and credibility with investors and lenders, making external financing less costly and easier when needed.
Strong Gross ProfitabilityHealthy gross margins imply attractive unit economics and pricing power in the core business. With disciplined operating cost control and scale, gross profitability supports a realistic path to positive operating margins and sustainable cash generation over the medium term.
Bears Say
Persistent Operating LossesChronic operating losses consume resources and limit the company’s ability to self-fund growth or R&D. Continued negative results over multiple years erode stakeholder confidence, require repeated external funding, and make it harder to demonstrate durable profitability to partners or payors.
Consistent Negative Free Cash FlowOngoing negative free cash flow means the business depends on external capital to maintain operations. That reliance increases dilution or debt risk, constrains long-term planning, and leaves the company vulnerable if capital markets tighten or funding costs rise materially.
Material Equity ErosionSignificant erosion of shareholder equity over several years signals value dilution from losses and reduces the balance-sheet buffer against setbacks. Weaker equity limits strategic flexibility, raises the threshold for return on invested capital, and may impair ability to pursue acquisitions or partnerships.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥134.00 and its highest was ¥417.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥2.67B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 8 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on May 14, 2026. The company reported -¥11.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.03.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 18,429,500 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
null
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―